Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.42 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.42 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10352111 | 0.91 | TDP1 (0.47) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL10352112 | 0.88 | PDE7A (0.42) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL30946522 | 0.84 | TDP1 (0.52) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL3077412 | 0.84 | TDP1 (0.52) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL29860351 | 0.84 | ALDH1A1 (0.43) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL1340438 | 0.84 | ALDH1A1 (0.43) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL28798959 | 0.83 | ATM (0.38) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL30924883 | 0.83 | TDP1 (0.50) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL825499 | 0.83 | TDP1 (0.50) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL57498 | 0.82 | TDP1 (0.54) | TDP1ATMALDH1A1HIF1AVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689130-A2 | METHODS AND COMPOSITIONS FOR ENHANCED EXPRESSION OF EXOGENOUS CASEINS IN TRANSGENIC PLANTS | Mozza Foods Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2024206469-A2 | METHODS AND COMPOSITIONS FOR ENHANCED EXPRESSION OF EXOGENOUS CASEINS IN TRANSGENIC PLANTS | Mozza Foods Inc. (US) | 2024-10-03 | — | — | WO | claimed |
| CN-116068167-A | Separation and detection method of extracellular biomacromolecule | 厦门福流生物科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-1268317-C | Cosmetic composition material containing exogenous ligand-receptor system and its application | OREAL (FR) | 2006-08-09 | — | — | CN | claimed |
| US-20040208843-A1 | Cosmetic composition comprising an exogenous ligand-receptor system adsorbed or covalently attached to keratin materials, and hair treatment using this composition or constituent elements thereof | L'OREAL S.A. (FR) | 2004-10-21 | — | — | US | claimed |
| CN-1494893-A | Cosmetic composition material containing exogenous ligand-receptor system and its application | ���ŷ� | 2004-05-12 | — | — | CN | claimed |
| EP-1402880-A1 | Cosmetic composition containing an exogenic ligand-receptor-system for binding to keratinic materials and hair treatment with this composition or it's constituting elements | L'OREAL (FR) | 2004-03-31 | — | — | EP | claimed |
| US-20040042993-A1 | Composition containing an active agent and a ligand-receptor system, and process | L'OREAL (FR) | 2004-03-04 | — | — | US | claimed |
| EP-1358867-A1 | Cosmetic composition containing a biotin compound an/or a complexing agent | L'OREAL (FR) | 2003-11-05 | — | — | EP | claimed |
| CN-1451370-A | Cosmetics composition and method for treating hair using same | OREAL (FR) | 2003-10-29 | — | — | CN | claimed |
| EP-0274264-A1 | Reverse passive particle agglutination reagent | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1988-07-13 | — | — | EP | claimed |
| EP-4689130-A2 | METHODS AND COMPOSITIONS FOR ENHANCED EXPRESSION OF EXOGENOUS CASEINS IN TRANSGENIC PLANTS | Mozza Foods Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3883865-B2 | SEAL OF A PORTION CAPSULE | GCS GERMAN CAPSULE SOLUTION GMBH (DE) | 2025-11-05 | — | — | EP | disclosed |
| US-12459728-B2 | Seal for a single serve capsule | GCS GERMAN CAPSULE SOLUTION GMBH (DE) | 2025-11-04 | — | — | US | disclosed |
| EP-3464530-B1 | CANDLE COMPRISING A COMPOSTABLE PLASTIC ELEMENT | CUP CANDLE GMBH (DE) | 2025-08-27 | — | — | EP | disclosed |
| US-4306019-A | IMMUNO CONJUGATE, COUPLING ANTIBODIES TO INSOLUBLE PARTICLES | EIKEN CHEMICAL CO., LTD. (JP) | 1981-12-15 | — | — | US | disclosed |
| EP-0037522-A2 | Derivatives of the heat stable enterotoxin of Escherichia coli, and their preparation | Smith Kline - RIT Société anonyme dite: (BE) | 1981-10-14 | — | — | EP | disclosed |
| US-4289756-A | Physiological preparation containing loaded cells of expanded volume in suspension, for preferential accumulation in spleen and liver | KERNFORSCHUNGSANLAGE JULICH GMBH (DE) | 1981-09-15 | — | — | US | disclosed |
| EP-0008682-A1 | Latex coated with protein material, process for the preparation of this latex, immunological reagent containing this latex, process for the preparation of this reagent, application of this reagent, testing procedure utilising this reagent and reagent kit containing this reagent | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-03-19 | — | — | EP | disclosed |
| US-4115543-A | USING ANTISERUM FROM FOWL INOCULATED WITH LIPOPOLYSACCHARIDE ANTIGEN | CANADIAN PATENTS & DEVELOPMENT LIMITED (CA) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040042993-A1 | Composition containing an active agent and a ligand-receptor system, and process | MC1R, BTD, MC5R | TDP1 4004/4885ATM 3733/4885ALDH1A1 967/4885 |
| US-20040208843-A1 | Cosmetic composition comprising an exogenous ligand-receptor system adsorbed or covalently attached to keratin materials, and hair treatment using this composition or constituent elements thereof | KRT18, CUTA, MC1R | TDP1 4574/4885ATM 1196/4885ALDH1A1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.